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Abstract Our progress in understanding pathological
disease mechanisms has led to the identiﬁcation of bio-
markers that have had a considerable impact on clinical
practice. It is hoped that the move from generalized to
stratiﬁed approaches, with the grouping of patients into
clinical/therapeutic subgroups according to speciﬁc bio-
markers, will lead to increasingly more effective clinical
treatments in the near future. This success depends on the
identiﬁcation of biomarkers that reﬂect disease evolution
and can be used to predict disease state and therapy
response, or represent themselves a target for treatment.
Biomarkers can be identiﬁed by studying relationships
between serum, tissue, or tumor microenvironment
parameters and clinical or therapeutic parameters at onset
and during the progression of the disease, using systems
biology. Given that multiple pathways, such as those
responsible for redox and immune regulation, are deregu-
lated or altered in tumors, the future of tumor therapy could
lie in the simultaneous targeting of these pathways using
extracellular and intracellular targets and biomarkers. With
this aim in mind, we evaluated the role of thioredoxin 1, a
key redox regulator, and CD30, a cell membrane receptor,
in immune regulation. Our results lead us to suggest that
the combined use of these biomarkers provides more
detailed information concerning the multiple pathways
affected in disease and hence the possibility of more
effective treatment.
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Introduction
The identiﬁcation of biomarkers has had a considerable
impact on clinical practice [1]. As a general rule, if tumor
biomarkers are to be of practical use they must either
reﬂect a particular characteristic or stage of disease or
represent a target for therapy. One of the best ways to
diagnose cancer early, aid in its prognosis, or predict
therapeutic response, is to use serum, tissue, or tumor
microenvironment biomarkers. Prognostic biomarkers are
used to predict the course of the disease, including recur-
rence and therefore have an important inﬂuence on the
choice of therapy [2]. Stratiﬁcation (predictive) biomarkers
predict the response to a drug before treatment starts by
classifying individuals as likely responders or non-
responders. These biomarkers are usually identiﬁed from
system biology-type studies that look at biological factors
that inﬂuence not only the pathogenesis but also the pro-
gression of the disease. Given that multiple pathways are
deregulated or altered in tumors, for example those
responsible for redox and immune regulation, it is more
than probable that future tumor therapy will involve
simultaneous targeting of pathways, through the use of
extracellular and intracellular prognostic and stratiﬁcation
biomarkers.
Redox system pathways regulate multiple cellular pro-
cesses including proliferation, cellular cycle, death, and
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functional, and apoptotic homeostasis of both immuno-
logical and tumoral cells. In these pathways, the cell thiol
redox state is a crucial mediator of multiple metabolic
signaling and transcriptional processes. In a metabolically
active cell, these redox system pathways maintain the
balance between oxidant and antioxidant factors, by regu-
lating the activation of speciﬁc transcription factors and the
production of substances that neutralize oxidants [5, 6].
However, when as in tumor, there are alterations in the
pathways of the redox system, the cell is no longer able to
produce antioxidant substances and adjust the balance
between oxidant and antioxidant factors, and therefore, it is
unable to respond appropriately to the body’s needs. This is
usually the reason why many anticancer agents including
radiation are ineffective, because the cytotoxicity induced
by them to make the cancer regress affects the antioxidant
activity of the redox system pathways, which are altered
for the reasons explained above [7]. Alterations in the
physiological pathways involved in the regulation of the
redox system have been identiﬁed in tumors [3–6, 8], and
research indicates that the functional inactivation of
immune cells by free radicals is an important immuno-
suppressive mechanism [8]. The re-establishment of
homeostasis within the physiological pathways of the redox
and immunological system is thus an important therapeutic
goal in tumor treatment, and biomarkers and targets are
essential for this.
Thioredoxin 1 (Trx1), a thiol-disulﬁde oxidoreductase,
is an essential physiological redox regulator in cellular
reactions [6]. As a result of oxidative stress, Trx1 activates
speciﬁc transcription factors in the nucleus that regulate
gene decoding for the production of substances that protect
cells from oxidative stress induced by free oxygen radicals.
Consequently, the fairly recent discovery that Trx1 cata-
lytically interacts with a target protein, the CD30 cell
membrane receptor (CD30R), on immune cells (T, B,
monocytes, dendritic cells, NK, eosinophils and granulo-
cytes), is of great clinical signiﬁcance [9–11]. CD30,
although not well known, is a molecule with a wide range
of action including regulatory signaling responsible for the
physiological homeostasis of T helper (Th)1/Th2/Th3/
Th17 cell network functions and hence for a productive
immune response [12–16]. The soluble (s) component of
CD30 (sCD30) and Trx1 both regulate CD30R functional
activation [9, 11], and abnormal increases in the levels of
both result in Th1-cell functional deﬁcit [12–14, 17, 18]
and have been noted in cancer [19, 20].
In light of the above, we assessed the potential of the
combined use of Trx and the CD30 system as a dual bio-
marker for extracellular and intracellular pathways and
propose their simultaneous targeting in tumor redox/
immunotherapy.
Trx1 system pathways and their importance
in physiological regulation
The redox system is one of the most important regulatory
systems of cell physiology in living organisms [6]. The Trx
system, consisting of Trx, thioredoxin reductase (TrxR),
and NADPH, is a key regulator in cellular redox reactions.
The cells of mammals contain two main Trx/TrxR systems:
the Trx1/Tx1R system that is normally found in the cyto-
plasm but under stress can migrate into the nucleus to
induce gene transcription or be secreted into the extracel-
lular environment to participate in the immune system
network and the Trx2/Trx2R system that is located in
mitochondria and endoplasmic reticulum and regulates
cellular apoptosis. There is also a mammalian testis-spe-
ciﬁc thioredoxin system that consists of three thioredoxins
that are only expressed in spermatids (named Sptrx-1,
Sptrx-2, and Sptrx-3) and an additional thioredoxin, highly
expressed in testis, but also present in lung and other cil-
iated tissues (named Txl-2) [21].
Trx1 consists of 108 amino acids; it contains a disulﬁde
bridge, and its catalytic site (-Trp-Cys
32-Gly-Pro-Cys
35-
Lys) uses hydrogen as a donor for oxidoreduction reac-
tions. Its reduced form is able to reduce ribose or phosphate
ribonucleosides, and the oxidized form is converted into
the reduced form by the ﬂavoprotein Tx1R, with the
intervention of NADPH, forming the ‘‘thioredoxin1 redox-
system’’ (Fig. 1). The Trx1 system operates in cellular
redox signaling by controlling the activity of transcription
factors such as NF-kB, p53, HIFa, AP-1, and the gluco-
corticoid receptor [6, 18, 22, 23].
Human T cells transformed by viruses produce a factor,
previously known as ADF, which is identical to human
Trx1. Trx1 is secreted by activated B lymphocytes, B
lymphocytes in chronic type-B leukemia, T lymphocytes,
and ﬁbroblasts. Trx1 is a potent growth factor and cell
survival factor and its expression rises in several types of
tumor especially more aggressive ones [24–29], and it is
generally related to tumor aggressiveness and inhibition of
the immune system [8]. Trx has been evaluated as a bio-
marker and therapeutic target for cancer [30–32], and it is
known that Trx levels can be used to indicate potential
chemotherapy resistance [8, 33, 34]. Indeed, an increase in
the level of Trx1 has been associated with decreased sur-
vival in tumor patients, and it is used as an independent
prognostic factor for progression and the expression of
VEGF and Ref-1 [29].
Trx1 catalytically interacts (Fig. 1) with a target protein
on immune cells, the tumor necrosis factor receptor
superfamily member 8 (TNFRSF8/CD30R) [9]. The redox
interaction is highly speciﬁc for both Trx1 and CD30R, and
the consequent redox state of CD30R determines its ability
to engage the cognate ligand CD30L and transduce signals
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to reﬂect CD30-dependent changes in lymphocyte effector
function because extracellular Trx levels regulate the redox
status of CD30R and binding of its ligand (CD30L) to
CD30R (Fig. 1).
The CD30R, CD30L, sCD30, and their importance
in immune system homeostasis
The CD30R, a member of the superfamily of TNFR/
NGFR receptors, was originally identiﬁed on primary
cultures of Hodgkin and Sternberg cells. CD30R is also
expressed on normal activated T cells, B cells, NK cells,
dendritic cells, and macrophages. Activation-induced
expression implicates CD30R as one of the regulators of
the ensuing immune response. The physiological function
of CD30R is not yet clear, but there is evidence that it
behaves as a signal transduction molecule. The interaction
between CD30R and CD30L on activated T cells, mono-
cytes, neutrophils, eosinophils, and B cells induces rapid
activation of gene transcription factors such as JunN-
kinase and NFKB. Furthermore, CD30R signals have been
shown to induce and regulate the integrated expression of
lymphocyte genes, cytotoxic effector molecules, nodal
trafﬁc, proliferation, and apoptosis [35]. Under inﬂamma-
tory conditions, CD30R expression increases and its in
vivo activation can be assessed and monitored by mea-
suring the level of sCD30, shed from the plasma mem-
brane upon CD30L binding to CD30R. CD30R was
originally identiﬁed as a promoter of Th2-cell develop-
ment and was used as a marker for Th2-cell populations
[36, 37]. However, further studies have identiﬁed
CD30R? cells in Th0, Th1, and Th2 proﬁles and shown
that during the course of a normal antigen response,
CD30R? cells are the main producers of IL5 and IFNc
[38]. The production of IFNc by CD30R? cells has been
linked to a TH1 response, while the production of IL4 to a
Th2 response. Current research indicates that CD30R and
sCD30 levels are involved in the homeostatic regulation of
the entire network of Th populations (Th1/Th2/Th3/Th17)
[12, 16].
Fig. 1 Trx1 has a conserved
catalytic site (-Trp-Cys-Gly-
Pro-Cys-Lys) that undergoes
reversible oxidation to the
cysteine-disulﬁde (Trx-S2) form
through the transfer of reducing
equivalents to a disulﬁde
substrate (X-S2). In health, the
oxidized (1) Trx1 form (Trx-S2)
is converted back to the
cysteine-thiol reduced (2) form
[Trx-(SH)2] by the NADPH-
dependent ﬂavoprotein
thioredoxin reductase (TrxR), so
maintaining balance between
oxidized and reduced Trx1
forms, and catalytically
interacts with CD30 cell
membrane receptor (CD30R) on
the immune cells (9). The
consequent oxidized (3) and
reduced (4) states of CD30R
determine its respective ability
(5) or inability (6) to engage its
ligand CD30L. In this way, it is
possible to transduce signals of
M and DC intracellular
pathways for Treg/Th1/Th17
cytokine production, leading to
balance of Th differentiation
into Treg/Th1/Th17 cells, for
immune response homeostasis
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in physiological homeostasis
The immune response has classically been divided into two
types: type 1 (Th1) the cell-mediated response, and type 2
(Th2) the humoral immune response. These responses are
regulated by Th1 and Th2 subsets of CD4? Th cells. Both
subsets produce interleukin (IL) 3, granulocyte monocyte
colony stimulator factor (GMCSF) and tumor necrosis
factor (TNF) a, but only Th1 cells produce IL2 and IFNc,
while Th2 cells produce other cytokines such as IL4, IL5,
IL6, and IL10. However, for a normal immune system
function, the polarization of the immune response into Th1
or Th2 cell types should not be absolute and the ratio of
these cells must vary according to physiological demand
and clinical conditions [39, 40], and return to initial levels
in physiological homeostasis. Each Th cytokine plays a
speciﬁc and crucial role in maintaining the balance within
the Th cell network, which is responsible for the normal
development of the immune response.
An additional CD4? Th-cell subset designated Th3 [41]
was later identiﬁed, and it is functionally characterized by
the production of transforming growth factor (TGF)b.
These cells have a very important T-regulatory role (T-reg)
on Th1- and Th2-cell functions, and increased effort is
being made in pharmacological research to understand the
mechanisms behind TGFb-mediated Th1/Th2 immuno-
logical suppression and/or stimulation.
A further population of T cells (Th17 cells) producing
IL17, IL6, TNF has also been identiﬁed, and it has been
reported that TGFb and IL6 interaction induces Th17-cell
differentiation in autoimmunity progression, by switching
T-cell generation from Treg to Th17 cells [42, 43]. On the
basis of this new Treg/Th1/Th2/Th17 model, Treg and
Th17 cells generate from reciprocal developmental path-
ways, and IL6 and TGFb appear to be the chief inducers of
Th-17 development while TGFb alone promotes the gen-
eration of Treg cells. CD30 appears to regulate the dif-
ferentiation of Th cells into Treg or Th17 cells [14], and
both Th1 and Th2 cytokines are required to reduce IL17.
Consequently, Th1 cells, long thought to mediate tissue
damage, might only be involved in the initiation of tissue
damage, without playing a decisive role. The cytokine
IL17, on the other hand, is now thought to have a major
role in various immune-mediated injuries including tumor
[44], organ-speciﬁc autoimmunity, allergic disorders of the
lung and skin, and microbial infections of the intestine and
nervous system.
In this new context, the immunological function of Th1-
cell population would be to antagonize Th17 pathways to
counter the onset of the above-mentioned diseases. Without
a doubt, a greater understanding of Treg/Th1/Th17 path-
ways will lead to a shift in perspective concerning the
functional basis of the immune system and lead to
improvements in the prevention and treatment of tumor
[44] and other immune pathologies. Clearly, given the
interconnecting role of the Trx1 and CD30 systems in the
regulation of Treg/Th1/Th17 pathways described earlier
(Fig. 1), they offer great potential as targets and biomark-
ers for new pharmacological treatments.
CD30R/sCD30 and their regulatory role in the Treg/
Th1/Th17 network
The use of the CD30 system as a biomarker and therapeutic
target for cancer (19) has been investigated by various
authors [19, 36, 37, 45]. The hypothesis that CD30 system
is responsible for the homeostasis of the Treg/Th1/Th17
cell network was conﬁrmed when it was found that
CD30R-mediated signals trigger changes in the levels of
production of several important Th cytokines involved in
the regulation of Treg/Th1/Th17 cell network homeostasis
[12–16, 35, 38, 44, 46]. These results also showed that
when interaction between CD30R and CD30L was blocked
by an abnormal increase in the levels of sCD30 [47], there
was an imbalance between Treg/Th1/Th17 cell functions
similar to the imbalance described for a monoclonal
CD30R antagonist [12] or monoclonal antibodies blocking
IL4 or IFNc activity [12, 46]. The expression and function
of the CD30R in dendritic cells (DCs) was also found to
have a fundamental role in the production of Th cytokines
and regulation of Treg/Th1/Th17 cell network homeostasis
[13, 14, 48]; abnormal increases in sCD30 levels produced
a disruption of DC CD30R-mediated signals by inducing
alterations in the immature DC and DC regulation of Treg/
Th1/Th17 cell immune response balance.
Thus, an abnormal increase in the levels of sCD30 can
produce an imbalance between Th cell network functions
(Fig. 2), by blocking CD30R-mediated signals [47]; sCD30
levels have also been found to be a prediction factor for
immunological risks [14, 19, 36, 37]. A lack of Treg can
also be a consequence of alterations in the normal regula-
tion of Th cell network through CD30R [12–14]. It has
become clear that DCs, through CD30R, play an essential
role in inducing and modulating Treg [12–16, 48], and
there is increasing evidence that targeted stimulation of
Treg may promote health and signiﬁcantly reduce the risk
of cancer [42, 49].
Hence, in conclusion, it would appear that (i) CD30R-
mediated signals are responsible for the homeostasis of
important Th cytokines involved in the regulation of Treg/
Th1/Th17 cell network homeostasis (Fig. 1 and Online
Resource 1); (ii) altered CD30/CD30L interaction due to
abnormal increases in sCD30 is responsible for a lack of
this regulation and the consequence of this is disease [44]
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used as an extracellular biomarker reﬂecting CD30R-
dependent changes in lymphocyte effector function (Fig. 3)
because extracellular sCD30 levels regulate the ligand
binding of CD30L to CD30R (Figs. 1, 3).
CD30 and the Trx1 system: their clinical, diagnostic,
and therapeutic potential
The pathways mediated by RCD30 are therefore respon-
sible for the homeostasis of the Th cell network, through
the regulation of Treg/Th1/Th17 cytokine production by
monocytes, immature and mature dendritic cells that direct
the differentiation of Th cells (Fig. 1).
However, an abnormal increase in sCD30 levels pre-
vents this regulation by close binding to CD30L, thus
blocking its interaction with membrane-bound CD30R [47]
(Fig. 2 and Online Resource 2). Hence, sCD30 could
potentially have a clinical, diagnostic, and therapeutic role
as an extracellular biomarker (Fig. 3) in immunopatholo-
gies such as tumors [10, 11].
Trx1, on the other hand, catalytically interacts (Fig. 1)
with CD30R [9] determining its ability to engage the
cognate ligand CD30L and transduce signals. Thus, Trx1
also affects CD30-dependent changes in lymphocyte
effector function by regulating its redox status and ligand
binding of CD30L. Increases in Trx1 levels (Fig. 2 and
Online Resource 2) have been linked to a lack of this
regulation: serum level values of Trx1 (Table 1), which in
normal individuals range between 10 and 80 ng/ml
(0.8–6.6 nM) [28], have been reported to be elevated in
several human primary cancers (Table 1), including lung,
colon, cervix, liver, pancreatic, colorectal, and squamous
cell cancer [28, 50, 51] (Table 1) and are generally related
to tumor aggressiveness [24–29] and inhibition of the
immunological system. Serum levels of sCD30 (Table 1),
which are usually below detectable levels or present at very
Fig. 2 In tumors, an increase in
Trx1 levels (1) leads to
abnormal redox cellular
regulation determining
imbalance between oxidant and
antioxidant Trx1(2) and
between oxidized and reduced
states of RCD30 (3), so
establishing RCD30 inability to
engage CD30L (4) and
transducer signals of
intracellular pathways for Treg/
Th1/Th17 cytokine production
(5). When levels of sCD30
(shed from the plasma
membrane upon CD30L binding
(6) increase (7), sCD30 binds to
CD30L with high afﬁnity
blocking CD30/CD30L
transmembrane signaling (8).
Thus, abnormal increases in the
levels of Trx1 and sCD30
(biomarkers 9 of extracellular
pathways of Trx1/CD30 target)
result in both deregulation of M
and DC pathways of Treg/Th1/
Th17 cytokine production
(biomarkers 5 of intracellular
pathways of Trx1/CD30 target)
and immunological deﬁcit:
Th17 expansion and Treg and
Th1-cell functional deﬁcit
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reported to be elevated in several human primary cancers
(Table 1), including colorectal, Hodgkin’s lymphoma,
prostate, lung and ovarian cancer, and are generally related
to tumor aggressiveness [52, 53] and inhibition of the
immunological system. Serum levels of sCD30 mirror Trx1
levels in physiological networks [9]: as Trx1 levels
increase in infections, allergies, autoimmune events, and
cancer, so do sCD30 levels; likewise Trx1 levels modulate
CD30R immunological functions during the immune
response as do sCD30 levels.
So in light of the facts that (i) RCD30 is highly expressed
on immune cells in inﬂammatory situations and levels of
sCD30 and Trx1 increase in the extracellular environment,
(ii) changes in the level of sCD30 and Trx1 within normal
ranges are linked to physiological immunological homeo-
stasis (Fig. 1 and Online Resource 1), while signiﬁcantly
high levels of sCD30 are related to the prevalence of Th17
suppressive immunity and Treg/Th1 immunological deﬁ-
ciency (Fig. 2 and Online Resource 2), and (iii) higher
levels of sCD30 and Trx1 have been found in pathological
processes including cancer (Table 1), it can be concluded
that (i) the Trx1/CD30 system could represent a new dual
target and biomarker in tumor treatments (Fig. 3) and (ii)
the levels of Trx1/sCD30 and Treg/Th1/Th17 cytokines
could be used as prognostic and stratiﬁcation biomarkers for
extracellular and intracellular pathways in therapy aimed at
the simultaneous optimization of the regulation of redox
and immune system functions (Fig. 3).
Conclusions
The identiﬁcation of prognostic and stratiﬁcation bio-
markers in clinical practice has resulted in the transition
from a generalized approach to a stratiﬁed one, with
treatment and diagnosis based on the identiﬁcation of
speciﬁc, subgroups of patients. However, this type of
approach relies on the deﬁnition of real clinical targets and
biomarkers which can be easily assessed, early in the dis-
ease process.
The potential of Trx and CD30 for use as targets and
biomarkers for tumors has been widely described in liter-
ature, and alterations in the physiological pathways
involved in the regulation of the redox and immunological
systems have been identiﬁed in various types of tumors
such as colorectal cancer, non-small cell lung carcinoma,
and breast cancer. However, we believe that it would be
more effective to target Trx and CD30 together to optimize
the regulation of redox and immune system functions, as by
combining these systems we combine the power of redox-
sensitive factors with the speciﬁcity of immune system
Fig. 3 Levels of Trx1/sCD30 and Treg/Th1/Th17 cytokine in serum,
tissue, or tumor microenvironment are prognostic and stratiﬁcation
biomarkers for clinical treatment. The CD30/Trx1 system is a
potential target in tumor therapy aimed at the simultaneous optimi-
zation of the redox and immune system regulation. Normal levels of
sCD30 and Trx1 are positive (beneﬁt) biomarkers reﬂecting the
normal functioning of extracellular pathways, while normal levels of
Treg/Th1/Th17 cytokines are positive (beneﬁt) biomarkers for the
normal functioning of intracellular pathways. Abnormal levels
(higher levels of sCD30, Trx1, and Th17 and lower levels of Treg
and Th1) are negative (risk) biomarkers for the abnormal functioning
of CD30/Trx1 target pathways and so for immunological deﬁcit and a
lack of response to therapy
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important new perspectives in stratiﬁed medicine.
In practice, changes in the level of sCD30 in the cellular
environment (serum, tissue, or tumor microenvironment) of
peripheral blood mononuclear cells, monocytes, and den-
dritic cells can be used as a biomarker for changes in
cytokine production pathways responsible for regulating
differentiation of Th cells into Th1, or Th2, or Th3 or Th17
cells (Fig. 1 and Online Resource 1). sCD30 levels within
physiological ranges is a positive prognostic biomarker as
it reﬂects homeostasis in the immunological system and
therapeutic response. A signiﬁcant increase in sCD30 lev-
els, on the other hand, is a negative biomarker, indicating
immunological deﬁcit and therapeutic risk (Fig. 2). How-
ever, both Trx1 and sCD30 can inﬂuence the ability of
CD30R to mediate the activation of intracellular signaling
by selectively inhibiting interaction with CD30L (Fig. 1
and Online Resource 1): Trx1 by catalytically changing
RCD30 structure and sCD30 by closely binding to CD30L
and blocking its binding to RCD30. Therefore, both com-
ponents need to be taken into consideration if they are to be
effectively used as biomarkers. Changes in levels of Trx1
and sCD30 are the functional extracellular biomarkers of
the new Trx1/CD30 target, and the levels of Treg/Th1/
Th17 cytokine production are the functional biomarkers of
intracellular pathways (Fig. 3). In addition, being able to
manipulate their roles in pathological processes may well
represent a non-invasive means of redirecting the physio-
logical system toward a beneﬁcial immunological and
therapeutic response (Online Resource 2).
In conclusion, these results indicate that the Trx1/CD30
system not only represents a dual prognostic and stratiﬁ-
cation biomarker for clinical diagnosis and therapeutic
risk/beneﬁt indices, but that it also has the potential to be a
dual target in translational research into the pharmacolog-
ical modulation of multiple redox and immunological
pathways aimed at the simultaneous optimization of the
regulation of redox and immune system functions.
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